Stanley C Erck insider trades: Maxcyte (MXCT) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Stanley reports to the SEC
Open-market buys and sales
24 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 13, 2025 | MXCT | ↑ Buy | 100,000 | $1.37 | $137K | Direct | Aug 13, 2025 (0d) |
| Nov 1, 2024 | MXCT | ↓ Sell | 47,689 | $3.72 | $177K | Direct | Nov 5, 2024 (4d) |
| Oct 2, 2024 | MXCT | ↓ Sell | 47,689 | $3.75 | $179K | Direct | Oct 2, 2024 (0d) |
| Sep 4, 2024 | MXCT | ↓ Sell | 47,689 | $4.02 | $192K | Direct | Sep 5, 2024 (1d) |
| Oct 4, 2021 | NVAX | ↓ Sell | 42,829 | $176.15 | $7.5M | Direct | Oct 5, 2021 (1d) |
| Oct 1, 2021 | NVAX | ↓ Sell | 49,000 | $175.10 | $8.6M | Direct | Oct 5, 2021 (4d) |
| Jul 2, 2021 | NVAX | ↓ Sell | 105,179 | $214.38 | $22.5M | Direct | Jul 6, 2021 (4d) |
| Nov 16, 2020 | NVAX | ↓ Sell | 52,316 | $90.65 | $4.7M | Direct | Nov 18, 2020 (2d) |
| Oct 1, 2020 | NVAX | ↓ Sell | 12,233 | $110.23 | $1.3M | Direct | Oct 1, 2020 (0d) |
| Sep 29, 2020 | NVAX | ↓ Sell | 29,112 | $109.95 | $3.2M | Direct | Sep 30, 2020 (1d) |
| May 14, 2018 | NVAX | ↑ Buy | 100,000 | $1.65 | $165K | Direct | May 15, 2018 (1d) |
| Nov 9, 2017 | NVAX | ↑ Buy | 100,000 | $1.13 | $113K | Direct | Nov 13, 2017 (4d) |
| May 11, 2017 | NVAX | ↑ Buy | 50,000 | $0.84 | $42K | Direct | May 11, 2017 (0d) |
| Mar 31, 2016 | NVAX | ↓ Sell | 424,778 | $5.19 | $2.2M | Direct | Apr 1, 2016 (1d) |
| Jan 31, 2016 | NVAX | ↑ Buy | 2,072 | $4.38 | $9K | Direct | Feb 1, 2016 (1d) |
| Jul 31, 2015 | NVAX | ↑ Buy | 3,207 | $2.28 | $7K | Direct | Aug 4, 2015 (4d) |
| Jan 31, 2015 | NVAX | ↑ Buy | 6,122 | $2.28 | $14K | Direct | Feb 3, 2015 (3d) |
| Jul 31, 2014 | NVAX | ↑ Buy | 6,788 | $2.28 | $15K | Direct | Aug 4, 2014 (4d) |
| Mar 25, 2014 | NVAX | ↑ Buy | 10,000 | $4.27 | $43K | Direct | Mar 25, 2014 (0d) |
| Jan 31, 2014 | NVAX | ↑ Buy | 11,868 | $2.29 | $27K | Direct | Feb 4, 2014 (4d) |
| Aug 19, 2011 | NVAX | ↑ Buy | 13,000 | $1.26 | $16K | Direct | Aug 23, 2011 (4d) |
| Aug 10, 2011 | NVAX | ↑ Buy | 50,000 | $1.24 | $62K | Direct | Aug 11, 2011 (1d) |
| Mar 12, 2009 | BCRX | ↑ Buy | 40,000 | $1.22 | $49K | Direct | Mar 16, 2009 (4d) |
| Jul 30, 2008 | IOMI | ↓ Sell | 138,236 | $6.56 | $906K | Direct | Jul 31, 2008 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other MXCT insiders
Open-market trades in the last 12 months
About Stanley C Erck's insider trades
Stanley C Erck is an insider at Maxcyte (MXCT). Since Jul 30, 2008, Stanley has reported 13 open-market purchases worth $700K and 11 sales worth $51.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (37 filings), option exercises (18 filings), shares withheld for taxes (7 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MXCT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.